Form D · Biotechnology
Andes Biotechnologies Global Inc.
Burlingame, CA · CIK 0001725267
Offering snapshot reported Dec 15, 2017 · SEC filing
- Reported sold
- $2.17M Offering amount: $15M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 30, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 15, 2017 | Initial | $2,169,220 | No comparison | 20 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-300898
Source: Form D, filed Dec 15, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Pablo Valenzuela | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
863 Mitten Road, Suite 101
Burlingame, CA, 94010
Burlingame, CA, 94010